CA-ANDERSEN-GLOBAL
14.12.2022 13:17:37 CET | Business Wire | Press release
Andersen — the leader in tax, valuation, financial advisory, and related consulting services — and The University of San Francisco (USF) have extended their partnership to create The Enterprise MBA program, in which eligible Andersen employees can earn an MBA in three to five years, fully-funded by Andersen on behalf of its employees. Modeled after the USF Masagung Graduate School of Management’s rigorous Part-Time MBA offering, the new program offers a standard MBA curriculum with courses tailored to address the specific professional development needs of Andersen employees in today’s complex, global business environment.
The new program is available to employees of Andersen member firms and collaborating firms, starting with U.S. employees and rolling out worldwide in 2023. Full- and part-time Andersen employees from senior associates to partners — regardless of tenure — are eligible for the program. Participating students must take three to four courses per year, delivered online and asynchronously, to complete the program requirements in five years. The first cohort of nearly 50 students started the pilot program in June 2022. USF welcomed 14 new Andersen students to the program in November 2022 and is targeting another 25-50 for January.
“Andersen strives to be the best professional services firm in the world and this new program is consistent with our dedication to continuous professional development and stewardship,” said Mark Vorsatz, CEO of Andersen. “To be the best in our industry, we have to attract and retain the best talent — that’s why we’re so committed to investing in our people. Working closely with the innovative educators at USF, we’ve built a customized program that reflects and enhances the work Andersen employees do on behalf of our clients every day. As the program grows, we expect it to be a unifying employee experience across our practice areas and global offices.”
Andersen’s offering is unique in the degree to which the firm was involved in course development, and the fact that the program is global in nature, fully funded by the firm, and does not have any kind of clawback, should employees enrolled in the program choose to leave the firm.
“Andersen’s culture is what keeps us together and what sets us apart,” continued Vorsatz. “Our investment in our people at all stages is just one component of how we are building and maintaining that culture.”
A Customized MBA to Meet Andersen’s Business Needs
Andersen and USF’s Masagung Graduate School of Management worked together to create a customized program, including content, delivery, modality, structure and timing, and even jointly creating a special elective class on the importance of company culture. In addition, in certain classes, Andersen senior staff can serve as adjunct professors to aid in instruction. Three trimesters of courses are offered each year: from early January to mid-to-late February; from early May to the end of August; and from early-November to mid-December. Given Andersen’s tax-centered business, program courses are offered outside of the busy tax seasons between March 1 and April 15 and between September 1 and October 15.
“This a truly unique and collaborative program and the close partnership between USF and Andersen sets a new standard for the future of corporate education,” said Otgo Erhemjamts, Dean of the School of Management at USF. “It demonstrates how educational institutions and companies can come together to address skill gaps and prepare organizations and their personnel for the rapidly evolving business world.”
Andersen and USF started their collaboration in 2014 when the organizations first partnered to provide Andersen personnel the opportunity to earn a Master of Laws in Taxation (LLM) or a Master of Legal Studies in Taxation (MLST) from the University of San Francisco School of Law. To date, more than 120 employees from 11 countries have graduated from those programs.
"The University of San Francisco, founded by the Jesuits in 1855, has long worked with the business community in and beyond the City to strengthen their talent pool,” stated USF President Rev. Paul J. Fitzgerald, S.J. “Our work with Andersen has been a terrific iteration of this work. The alignment of our cultures makes this excellent teaching/learning experience possible. We are especially grateful to Mr. Vorsatz for envisioning this dynamic partnership."
Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 13,000 professionals worldwide and a presence in over 390 locations through its member firms and collaborating firms.
About the USF School of Management
Founded in 1925, University of San Francisco’s School of Management is on the forefront of educating the next generation of conscious, mindful business leaders. Each year those students join the over 40,000 School of Management alumni around the world to create ethical and innovative change in the private, public, and non-profit management sectors. The School of Management is accredited by the Western Association of Schools and Colleges Senior College and University Commission (WSCUC) and the Association to Advance Collegiate Schools of Business (AACSB).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005400/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
